REG - Silence Therapeutics - Results of Annual General Meeting

Silence TherapeuticsAnnouncement

15/06/2021 17:55

RNS Number : 0091C
  
Silence Therapeutics PLC
  
15 June 2021
  
 

 
 
Results of Annual General Meeting
15 June 2021
 
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its Annual General Meeting held today, 15 June 2021, all resolutions set out in the notice of meeting were duly passed on a poll. 
 
The votes were as follows:
 




Resolution

*Indicates special resolution 


Votes for


%


Votes against


%


Votes total*


% of ISC voted


Votes withheld




1 - Receive and adopt the 2020 UK Annual Report 


36,083,741


100.00%


0


0.00%


36,083,741


40.23%


21,958




2 - Re-appoint Mark Rothera as a director


36,030,331


99.79%


74,748


0.21%


36,105,079


40.26%


620




3 - Re-appoint Dr. Michael Davidson as a director


36,080,250


99.93%


24,829


0.07%


36,105,079


40.26%


620




4 - Re-appoint Dr. Giles Campion as a director


36,042,763


99.83%


62,316


0.17%


36,105,079


40.26%


620




5 - Approve the directors' remuneration report 


35,285,210


97.73%


820,064


2.27%


36,105,274


40.26%


425




6 - Approve the directors' remuneration policy 


35,240,884


97.61%


864,390


2.39%


36,105,274


40.26%


425




7 - Re-appoint PricewaterhouseCoopers LLP as auditors of the Company 


27,375,812


97.44%


719,478


2.56%


28,095,290


31.33%


8,010,409




8 - Authorise the directors to allot shares and grant rights to subscribe for, or convert securities into, shares 


31,771,639


99.82%


57,480


0.18%


31,829,119


35.49%


4,276,580




9 - Disapply pre-emption rights in connection with an allotment of equity securities for cash*


29,459,251


97.48%


761,703


2.52%


30,220,954


33.70%


5,884,745




 
The number of the Company's ordinary shares in issue as at the date of the meeting was 89,685,448 ordinary shares of nominal value 5p each.
 
*Excludes votes withheld.
A vote withheld is not a vote in law and has not been counted in the calculation of the proportion of votes for and against the resolutions.
 
 
Enquiries:
 




Silence Therapeutics plc
 Gem Hopkins, Head of IR & Corporate Communications


Tel:  +1 (646) 637-3208




 
Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
 


 
Tel:  +44 (0) 20 7597 5970




European PR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com 
 


Tel: +44 (0) 20 3709 5700




 
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
RAGFLFERRFIELIL